![Renejix CDMO Partner for Small Molecule Oral Dosage Forms](https://www.pharmacompass.com/image/flap/renejix-w35-desktop-header-01gif-33629.gif)
![Renejix CDMO Partner for Small Molecule Oral Dosage Forms](https://www.pharmacompass.com/image/flap/renejix-w35-mob-header-01gif-17728.gif)
API Suppliers
0
US DMFs Filed
0
CEP/COS Certifications
0
JDMFs Filed
0
EU WC
0
Listed Suppliers
0
0
0
USA (Orange Book)
0
Europe
0
Canada
0
Australia
0
South Africa
0
Uploaded Dossiers
0
U.S. Medicaid
0
Annual Reports
0
0
USFDA Orange Book Patents
0
USFDA Exclusivities
0
Blog #PharmaFlow
0
News
EDQM
0
USP
0
JP
0
Other Listed Suppliers
0
0
https://www.prnewswire.com/news-releases/senhwa-biosciences-announces-first-patient-dosed-in-the-phase-ii--study-of-silmitasertib-in-patients-with-community-acquired-pneumonia-associated-with-viral-infection-in-taiwan-302094217.html
https://www.prnewswire.com/news-releases/senhwa-biosciences-received-us-fda-ind-approval-for-phase-ii-study-of-silmitasertib-in-patients-with-community-acquired-pneumonia-cap-associated-with-viral-infection-301994554.html
https://www.prnewswire.com/news-releases/senhwa-biosciences-announces-first-patient-successfully-dosed-in-taiwan-phase-ii-study-of-silmitasertib-in-hospitalized-adults-with-covid-19-301982962.html
https://www.prnewswire.com/news-releases/senhwa-biosciences-announces-ind-submission-to-us-fda-for-phase-ii-study-of-silmitasertib-in-patients-with-community-acquired-pneumonia-cap-associated-with-viral-infection-301961780.html
https://www.prnewswire.com/news-releases/at-the-2022-aad-annual-meeting-senhwa-presents-positive-initial-data-from-clinical-trial-of-silmitasertib-used-to-treat-patients-with-advanced-basal-cell-carcinoma-301511415.html
https://www.prnewswire.com/news-releases/senhwas-silmitasertib-receives-us-fda-orphan-drug-designation-for-the-treatment-of-biliary-tract-cancer-301464631.html
https://www.prnewswire.com/news-releases/senhwas-silmitasertib-receives-us-fda-orphan-drug-designation-for-the-treatment-of-medulloblastoma-301447119.html
https://www.prnewswire.com/news-releases/senhwa-clinical-data-abstract-for-silmitasertib-in-patients-with-advanced-basal-cell-carcinoma-accepted-for-2022-aad-annual-meeting-301446148.html
https://www.clinicaltrialsarena.com/news/senhwa-positive-data-covid-trial/
https://www.prnewswire.com/news-releases/senhwa-announces-acceptance-of-early-positive-covid-19-phase-ii-study-abstract-for-presentation-at-the-isirv-who-conference-301385476.html
https://www.prnewswire.com/news-releases/senhwas-silmitasertib-covid-19-drug-candidate-receives-positive-interim-review-from-data-monitoring-committee-to-proceed-301365769.html
https://www.prnewswire.com/news-releases/senhwas-silmitasertib-receives-us-fda-fast-track-designation-for-the-treatment-of-recurrent-sonic-hedgehog-driven-medulloblastoma-301358557.html
https://www.prnewswire.com/news-releases/senhwa-announces-the-first-patient-enrolled-in-an-investigator-initiated-trial-of-silmitasertib-as-a-treatment-for-patients-with-severe-covid-19-301213001.html
https://www.biospace.com/article/releases/care-ga-receives-study-may-proceed-letter-from-us-fda-to-initiate-phase-ii-clinical-trial-of-senhwa-s-silmitasertib-in-covid-19-patients/
https://www.prnewswire.com/news-releases/senhwa-announces-multiple-ind-application-submissions-to-us-fda-for-silmitasertib-as-a-potential-treatment-for-covid-19-301164719.html
https://en.prnasia.com/releases/global/senhwa-announces-multiple-ind-application-submissions-to-u-s-fda-for-silmitasertib-as-a-potential-treatment-for-covid-19-297038.shtml
https://www.biospectrumasia.com/news/39/16714/taiwan-reports-first-covid-19-patient-recovery-with-eind-silmitasertib-treatment.html
https://en.prnasia.com/releases/global/coronavirus-breakthrough-senhwa-reports-first-eind-silmitasertib-treated-severe-covid-19-patient-discharged-following-five-days-of-treatment-291291.shtml
https://en.prnasia.com/releases/global/senhwa-biosciences-s-silmitasertib-receives-rare-pediatric-disease-designation-from-u-s-fda-for-treatment-of-recurrent-sonic-hedgehog-medulloblastoma-284762.shtml
https://www.biospectrumasia.com/news/26/16230/senhwa-bio-explores-silmitasertib-for-covid-19-treatment.html
https://www.prnewswire.com/news-releases/coronavirus-breakthrough-new-study-highlights-senhwa-biosciences-silmitasertib-as-potential-treatment-for-covid-19-301086613.html